Alliances
Collaboration will leverage Lantern’s proprietary AI platform and NCI’s platform to better predict patients’ tumor responses to specific drug classes and therapeutics
Swiss pharma giant Novartis has partnered with tech giant Microsoft and launched its Novartis AI innovation lab as a means to leverage data and artificial intelligence to transform drug discovery and development.
Partnership combines global CDMO services with industry leading cellular orchestration platform
Eisai Co., Ltd. and Nichi-Iko Pharmaceutical have entered into a comprehensive collaboration agreement for the generic pharmaceutical business in China.
Insilico Biotechnology AG and the Janssen Pharmaceutical Companies of Johnson & Johnson announced an agreement to apply Insilico’s predictive Digital Twins for the early selection of high-performing cells to further boost efficiency and throughput of their cell line development workflow.
Less than one year after signing agreement, the GPCR expert has reached key discovery milestones in two independent projects
Eisai Co., Ltd. and Tokio Marine & Nichido Fire Insurance Co., Ltd. announced that the companies have entered into a business alliance agreement for co-existence and prevention of dementia.
Biocrates Life Sciences AG, the global leader in targeted metabolomics, and Helmholtz Zentrum München, the German Research Center for Environmental Health, enter a new phase of collaboration in their 10-year partnership.
Polarean Imaging plc, the medical-imaging technology company, with a proprietary drug-device combination product, notes the announcement made by its partner company, Amphion Innovations Plc that Amphion has agreed to amend the terms of the Loan Facility with Amphion’s debt provider.
BioIVT will help to generate drug discovery target validation data and characterize novel therapeutics
PRESS RELEASES